Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| In patients with compromised lungs, we think that the less breath required through a low-flow device will be seen as a fundamental benefit by both patients and prescribers |
| We continue to post solid growth in our current business with our third consecutive quarter of record revenues for Tyvaso and revenue growth for our US Remodulin business, despite the presence of competition in the market for the past five years |
| I think from a demand standpoint for the Tyvaso franchise, we were really happy with the demand metrics in the fourth quarter |
| Finally, TYVASO, Worldwide TYVASO revenue was up 45% to $351 million, our highest quarter ever |
| So that – maybe, you could share a little bit about the amazing job our clinical operations team does, in terms of ensuring safety and our stellar pharmaco vigilance and drug safety group |
| International ordering driven by our partner in Japan, was strong over a comparably soft quarter in 2022 |
| We expect this platform strategy to emerge, as a competitive advantage over other potential DPI products should they reach the market |
| Importantly, we saw meaningful growth across our entire suite of products, like the Tyvaso franchise, Remodulin in the US, Orenitram and Unituxin |
| Our growth in PH-ILD and continued leadership in pulmonary arterial hypertension also known as PAH has led our nebulized Tyvaso and our Tyvaso DPI products combining to become the most prescribed prostacyclin therapy in the United States |
| As Martine noted, today we reported our highest revenue quarter ever at $615 million, up 25% from the fourth quarter of 2022 and record annual revenues of more than $2.3 billion, up 20% over 2022 |
| revenue was up 40% to $337 million and was the highest quarter ever |
| These programs should enable us to continue our double-digit annual growth trend through the second half of the decade |
| We believe ralinepag's once-daily dosing, sustained release profile, and titratability could position it favorably against the other oral prostacyclin receptor agonists on the market as well as other therapies for PAH patients |
| So again, we have been well prepared for the IRA years ahead of time and all that great groundwork and preparation is certainly paying off |
| We have a solid commercial business, posting record results with continued strong growth ahead, a pipeline of novel therapies that continue our strong double-digit revenue growth and a long-term plan to address one of the largest, critical, unmet medical needs in medicine all while helping our patients, employees and shareholders succeed |
| From an inventory standpoint, as Martine alluded to and as I said in my opening remarks, I think we feel really good about where we are from an inventory standpoint |
| So, from a demand standpoint just really, really happy with how the commercial teams are performing, the continued uptake of Tyvaso DPI, in both PAH and PH-ILD, and then generally the continued growth in the PH-ILD business |
| I'm thrilled that we're in such a great position at United Therapeutics |
| So, it's really nice to see that we were able to really kind of buck that trend on the referral side |
| We're extremely proud of our continued record performance in this past quarter and the entire year and we think we're in the early stages of sustainable growth for our current commercial portfolio |
| We yet again achieved 20% plus quarterly and annual revenue growth for the fourth quarter and the full year 2023 |
| Congratulations to the 1,200 Unitherians who worked tirelessly every day to help us achieve our third straight quarter of record revenue and our second straight year of record revenue |
| Of course, both our first and second waves of growth are subject to clinical trial outcomes, regulatory approvals, new competitive entrants and the potential impacts of the Inflation Reduction Act, but we feel good about our prospects for meeting these revenue growth targets |
| On top of our record performance in the fourth quarter of 2023 earlier this year, we received important external validation of the value of our Tyvaso DPI business through a royalty transaction executed by our partners at MannKind Corporation |
| Third, titratability is better than non-titratability |
| Ralinepag provides 24-hour coverage with higher potency than the other oral prostacyclin agonists as demonstrated by in-vitro assays and ralinepag significantly demonstrated more than 20% improvement in pulmonary vascular resistance in a Phase 2 study |
| Super, super exciting and wow, just breathing so much hope into the entire transplant space |
| Worldwide Unituxin revenue of $54 million in the fourth quarter was up 48% from the prior year quarter and U.S |
| We expect this momentum to continue in the U.S., as we had a near record number of referrals and starts during the fourth quarter, driven in part by interest in the EXPEDITE study results |
| Really nice quarter Martine and team, and just keep it going |
| Statement |
|---|
| Worldwide Remodulin revenue of $115 million for the fourth quarter was down 6% from last year, primarily impacted by International order timing |
| And therefore, our PAP utilization will continue to decline over the balance of this year and then into 2025 |
| The problem for PAH, IPF, and many other patients with end-stage organ disease is that there aren't enough donors and transplantable organs available to address the need |
| Acute liver failure is a devastating condition with no approved therapies |
| So because of all of those factors lower out-of-pocket, eventually able to spread it out over 12 months and covers all of the drugs, I think what we're going to see is a reduction in the utilization of our patient assistance program |
| Nothing ever bumps safety |
| And really I think it's a question, as it relates to competitors, I think it's really a question for prescribers and for those manufacturers, to be honest |
| But coming out of the gate so to speak I would say Remodulin is probably the least likely to be impacted because patients that are on Remodulin tend to be more advanced patients more severe patients |
| We had a surprising number of patients that were able to switch over from patient assistance to commercial drug in the first quarter |
| And for many organ donations, one life sadly must be lost to save another |
| New patient start, which is unusual given we talk a lot about the cyclicality or the seasonality, particularly in the fourth quarter with the holidays and the fewer shipping days |
Please consider a small donation if you think this website provides you with relevant information